Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model

Biochemical Pharmacology

Volumn 79, Issue 6, 2010, Pages 880-887

  Liu, Jun Yan ^a   Yang, Jun ^a   Inceoglu, Bora ^a   Qiu, Hong ^b   Ulu, Arzu ^a   Hwang, Sung Hee ^a   Chiamvimonvat, Nipavan ^b   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arachidonic acid; Eicosanoid; Interaction; Metabolomics; Synergism

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXYL]BENZOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 2; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; ICOSANOID; LIPOPOLYSACCHARIDE; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GENE DISRUPTION; GENE EXPRESSION PROFILING; HYPOTENSION; KNOCKOUT GENE; MALE; METABOLITE; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEPSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; ASPIRIN; BENZOIC ACIDS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYEICOSATETRAENOIC ACIDS; INDOLES; INFLAMMATION; LIPOPOLYSACCHARIDES; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; UREA;

EID: 74149087378     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.025     Document Type: Article

References (63)

1. Levick S.P., Loch D.C., Taylor S.M., and Janicki J.S. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol 178 (2007) 641-646
2. Sciulli M.G., Capone M.L., Tacconelli S., and Patrignani P. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 57 Suppl. (2005) 66-85
3. Claria J., and Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 11 (2005) 3431-3447
4. Wickelgren I. Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation. Science 303 (2004) 941
5. Chen X.X., Sood S., Yang C.S., Li N., and Sun Z. Five-lipoxygenase pathway of arachidonic acid metabolism in carcinogenesis and cancer chemoprevention. Curr Cancer Drug Targets 6 (2006) 613-622
6. Evans J.F., Ferguson A.D., Mosley R.T., and Hutchinson J.H. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 29 (2008) 72-78
7. Peters-Golden M. Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med 157 (1998) S227-S232
8. Ferguson A.D., McKeever B.M., Xu S., Wisniewski D., Miller D.K., Yamin T.T., et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317 (2007) 510-512
9. Ago H., Kanaoka Y., Irikura D., Lam B.K., Shimamura T., Austen K.F., et al. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 448 (2007) 609-612
10. Charlier C., and Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 38 (2003) 645-659
11. Spector A.A., Fang X., Snyder G.D., and Weintraub N.L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43 (2004) 55-90
12. Campbell W.B. New role for epoxyeicosatrienoic acids as anti-inflammatory mediators. Trends Pharmacol Sci 21 (2000) 125-127
13. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103 (2006) 18733-18738
14. Node K., Huo Y.Q., Ruan X.L., Yang B.C., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999) 1276-1279
15. Imig J.D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol-Renal 289 (2005) F496-F503
16. Sarkis A., and Roman R.J. Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr Drug Metab 5 (2004) 245-256
17. Seubert J.M., Zeldin D.C., Nithipatikom K., and Gross G.J. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82 (2007) 50-59
18. Elbekai R.H., and El-Kadi A.O.S. Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol Therapeut 112 (2006) 564-587
19. Doggrell S.A., and Cytochrome. P-450: a new target in the heart and coronary circulation. Drug Future 30 (2005) 261-269
20. Newman J.W., Morisseau C., and Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 44 (2005) 1-51
21. Morisseau C., Schmelzer K., Pedersen T., Eiserich J., Pinkerton K., Imig J., et al. Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. FASEB J 20 (2006) A669-A670
22. Imig J.D., Zhao X.Y., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46 (2005) 975-981
23. Zhao X.Y., Inscho E.W., Morisseau C., Hammock B.D., and Imig J.D. Soluble epoxide hydrolase regulates renal microvascular angiotensin II reactivity in hypertension. FASEB J 16 (2002) A418-A420
24. Imig J.D., Zhao X.Y., Capdevila J.H., Morisseau C., and Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
25. Imig J.D. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 24 (2006) 169-188
26. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102 (2005) 9772-9777
27. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., and Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 102 (2005) 2186-2191
28. Olearczyk J.J., Quigley J.E., Mitchell B.C., Yamamoto T., Kim I.H., Newman J.W., et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) 116 (2009) 61-70
29. Inceoglu B., Schmelzer K.R., Morisseau C., Jinks S.L., and Hammock B.D. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82 (2007) 42-49
30. Ng V.Y., Morisseau C., Falck J.R., Hammock B.D., and Kroetz D.L. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc 26 (2006) 2462-2468
31. Schmelzer K.R., Inceoglu B., Kubala L., Kim I.H., Jinks S.L., Eiserich J.P., et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103 (2006) 13646-13651
32. Seubert J.M., Sinal C.J., Graves J., DeGraff L.M., Bradbury J.A., Lee C.R., et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99 (2006) 442-450
33. Davis B.B., Morisseau C., Newman J.W., Pedersen T.L., Hammock B.D., and Weiss R.H. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther 316 (2006) 815-821
34. Jin L.M., Foss C.E., Zhao X.Y., Mills T.M., Wang M.H., McCluskey L.P., et al. Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB J 20 (2006) 539-541
35. Borgdorff P., Tangelder G.J., and Paulus W.J. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. J Am Coll Cardiol 48 (2006) 817-823
36. Domoki F., Nagy K., Temesvari P., and Bari F. Selective inhibitors differentially affect cyclooxygenase-dependent pial arteriolar responses in newborn pigs. Pediatr Res 57 (2005) 853-857
37. Leach M., Hamilton L.C., Olbrich A., Wray G.M., and Thiemermann C. Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone. Br J Pharmacol 124 (1998) 586-592
38. Brindle J.T., Antti H., Holmes E., Tranter G., Nicholson J.K., Bethell H.W.L., et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics. Nat Med 8 (2002) 1439-1444
39. Lewis G.D., Wei R., Liu E., Yang E., Shi X., Martinovic M., et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118 (2008) 3503-3512
40. Lindon J.C., Keun H.C., Ebbels T.M.D., Pearce J.M.T., Holmes E., and Nicholson J.K. The consortium for metabonomic toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6 (2005) 691-699
41. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 48 (2002) 155-171
42. Wikoff W.R., Pendyala G., Siuzdak G., and Fox H.S. Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J Clin Invest 118 (2008) 2661-2669
43. Yang J., Schmelzer K., Georgi K., and Hammock B.D. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem 81 (2009) 8085-8093
44. Sinal C.J., Miyata M., Tohkin M., Nagata K., Bend J.R., and Gonzalez F.J. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275 (2000) 40504-40510
45. Luria A., Weldon S.M., Kabcenell A.K., Ingraham R.H., Matera D., Jiang H.P., et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282 (2007) 2891-2898
46. Hwang S.H., Tsai H.J., Liu J.Y., Morisseau C., and Hammock B. Orally bioavailable potent soluble epoxide hydrolase (sEH) inhibitors. J Med Chem 50 (2007) 3825-3840
47. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., and Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106 (2002) 1282-1287
48. Paul L., Fraifeld V., and Kaplanski J. Evidence supporting involvement of leukotrienes in LPS-induced hypothermia in mice. Am J Physiol-Reg I 276 (1999) R52-R58
49. Liu J.Y., Tsai H.J., Hwang S.H., Jones P.D., Morisseau C., and Hammock B.D. Pharmacokinetic optimization of four soluble epoxide hydrolase (sEH) inhibitors for use in a murine model of inflammation. Br J Pharmacol 156 (2009) 284-296
50. Liu J.Y., Park S.H., Morisseau C., Hwang S.H., Hammock B.D., and Weiss R.H. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther 8 (2009) 2193-2203
51. Capdevila J.H., Falck J.R., and Estabrook R.W. Cytochrome-P450 and the Arachidonate Cascade. FASEB J 6 (1992) 731-736
52. Weinberg J.R., Boyle P., Meager A., and Guz A. Lipopolysaccharide, tumor-necrosis-factor, and interleukin-1 interact to cause hypotension. J Lab Clin Med 120 (1992) 205-211
53. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101 (1998) 311-320
54. Dettmer K., and Hammock B.D. Metabolomics-a new exciting field within the "omics" sciences. Environ Health Perspect 112 (2004) A396-A397
55. Back M., Sultan A., Ovchinnikova O., and Hansson G.K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 100 (2007) 946-949
56. Jawien J., Gajda M., Rudling M., Mateuszuk L., Olszanecki R., Guzik T.J., et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 36 (2006) 141-146
57. Titos E., Claria J., Planaguma A., Lopez-Parra M., Gonzalez-Periz A., Gaya J., et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J Leukoc Biol 78 (2005) 871-878
58. Byrum R.S., Goulet J.L., Griffiths R.J., and Koller B.H. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J Exp Med 185 (1997) 1065-1075
59. Voelkel N.F., Tuder R.M., Wade K., Hoper M., Lepley R.A., Goulet J.L., et al. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 97 (1996) 2491-2498
60. Cianchi F., Cortesini C., Magnelli L., Fanti E., Papucci L., Schiavone N., et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 5 (2006) 2716-2726
61. Picard P., Bazin J.E., Conio N., Ruiz F., and Schoeffler P. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. Pain 73 (1997) 401-406
62. Delaney J.A., Opatrny L., Brophy J.M., and Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Can Med Assoc J 177 (2007) 347-351
63. Graham D.Y., and Smith J.L. Aspirin and the stomach. Ann Intern Med 104 (1986) 390-398